Feasibility of Switching From Immediate-release Quetiapine Fumarate to Sustained-release Quetiapine Fumarate for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing Feasibility of Switching From Immediate-release Quetiapine Fumarate to Sustained-release Quetiapine Fumarate for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Switching From IR Seroquel may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Switching From IR Seroquel, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Australia, in Bulgaria, and in Canada.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateNovember 2004
Recruitment status
Completed
Enrollment listed in the registry
454
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, Canada, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00206128
Official title
6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00206128. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Australia · 1 site
Research Site
QLD
Site status: Not listed — confirm with the team
Bulgaria · 3 sites
Research Site
Burgas
Site status: Not listed — confirm with the team
Research Site
Radnevo
Site status: Not listed — confirm with the team
Research Site
Varna
Site status: Not listed — confirm with the team
Canada · 9 sites
Research Site
Vancouver, British Columbia
Site status: Not listed — confirm with the team
Research Site
Aurora, Ontario
Site status: Not listed — confirm with the team
Research Site
Burlington, Ontario
Site status: Not listed — confirm with the team
Research Site
Mississauga, Ontario
Site status: Not listed — confirm with the team
Research Site
Orléans, Ontario
Site status: Not listed — confirm with the team
Research Site
Toronto, Ontario
Site status: Not listed — confirm with the team
Research Site
Québec, Quebec
Site status: Not listed — confirm with the team
Research Site
Sherbrooke, Quebec
Site status: Not listed — confirm with the team
Research Site
Prince Albert, Saskatchewan
Site status: Not listed — confirm with the team
Estonia · 3 sites
Research Site
Põltsamaa
Site status: Not listed — confirm with the team
Research Site
Tallinn
Site status: Not listed — confirm with the team
Research Site
Tartu
Site status: Not listed — confirm with the team
Finland · 3 sites
Research Site
Helsinki
Site status: Not listed — confirm with the team
Research Site
Mikkeli
Site status: Not listed — confirm with the team
Research Site
Turku
Site status: Not listed — confirm with the team
Germany · 7 sites
Research Site
München, Bavaria
Site status: Not listed — confirm with the team
Research Site
Göttingen, Lower Saxony
Site status: Not listed — confirm with the team
Research Center
Aachen, North Rhine-Westphalia
Site status: Not listed — confirm with the team
Research Site
Aachen, North Rhine-Westphalia
Site status: Not listed — confirm with the team
Research Site
Jena, Thuringia
Site status: Not listed — confirm with the team
Research Site
Halle
Site status: Not listed — confirm with the team
Research Site
Marburg
Site status: Not listed — confirm with the team
Hungary · 6 sites
Research Site
Budapest
Site status: Not listed — confirm with the team
Research Site
Debrecen
Site status: Not listed — confirm with the team
Research Site
Gyula
Site status: Not listed — confirm with the team
Research Site
Nagykálló
Site status: Not listed — confirm with the team
Research Site
Szeged
Site status: Not listed — confirm with the team
Research Site
Székesfehérvár
Site status: Not listed — confirm with the team
Italy · 7 sites
Research Site
Bologna, BO
Site status: Not listed — confirm with the team
Research Site
Cagliari, CA
Site status: Not listed — confirm with the team
Research Site
Città di Castello, PG
Site status: Not listed — confirm with the team
Research Site
Ellera Di Corciano, PG
Site status: Not listed — confirm with the team
Research Site
Torino, TO
Site status: Not listed — confirm with the team
Research Site
Bassano del Grappa, VI
Site status: Not listed — confirm with the team
Research Site
Quartu Sant'Elena
Site status: Not listed — confirm with the team
Latvia · 2 sites
Research Site
Riga
Site status: Not listed — confirm with the team
Research Site
Sigulda
Site status: Not listed — confirm with the team
Lithuania · 4 sites
Research Site
Ziegzdrai, Kaunas County
Site status: Not listed — confirm with the team
Research Site
Klapeda
Site status: Not listed — confirm with the team
Research Site
Šiauliai
Site status: Not listed — confirm with the team
Research Sitte
Vilnius
Site status: Not listed — confirm with the team
Spain · 6 sites
Research Site
Jerez de la Frontera, Cádiz
Site status: Not listed — confirm with the team
Research Site
Alcobendas, Madrid
Site status: Not listed — confirm with the team
Research Site
Colmenar Viejo, Madrid
Site status: Not listed — confirm with the team
Research Site
Madrid, Madrid
Site status: Not listed — confirm with the team
Research Site
Móstoles, Madrid
Site status: Not listed — confirm with the team
Research Site
Villamartín
Site status: Not listed — confirm with the team
United States · 18 sites
Research Site
Birmingham, Alabama
Site status: Not listed — confirm with the team
Research Site
Anaheim, California
Site status: Not listed — confirm with the team
Research Site
Cerritos, California
Site status: Not listed — confirm with the team
Research Site
Garden Grove, California
Site status: Not listed — confirm with the team
Research Site
National City, California
Site status: Not listed — confirm with the team
Research Site
Pasadena, California
Site status: Not listed — confirm with the team
Research Site
San Diego, California
Site status: Not listed — confirm with the team
Research Site
Santa Ana, California
Site status: Not listed — confirm with the team
Research Site
North Miami, Florida
Site status: Not listed — confirm with the team
Research Site
Atlanta, Georgia
Site status: Not listed — confirm with the team
Research Site
Hoffman Estates, Illinois
Site status: Not listed — confirm with the team
Research Site
New Orleans, Louisiana
Site status: Not listed — confirm with the team
Research Site
Jackson, Mississippi
Site status: Not listed — confirm with the team
Research Site
Clementon, New Jersey
Site status: Not listed — confirm with the team
Research Site
Staten Island, New York
Site status: Not listed — confirm with the team
Research Site
Austin, Texas
Site status: Not listed — confirm with the team
Research Site
Houston, Texas
Site status: Not listed — confirm with the team
Research Site
Richmond, Virginia
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Seroquel SR. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by AstraZeneca, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
